

# Rafael Tabares-Seisdedos

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2916704/rafael-tabares-seisdedos-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

187  
papers

42,649  
citations

64  
h-index

205  
g-index

205  
ext. papers

61,215  
ext. citations

10.2  
avg, IF

6  
L-index

#	Paper	IF	Citations
187	Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019.. <i>Lancet Public Health, The</i> , <b>2022</b> ,	22.4	95
186	Burden of non-communicable diseases among adolescents aged 10-24 years in the EU, 1990-2019: a systematic analysis of the Global Burden of Diseases Study 2019.. <i>The Lancet Child and Adolescent Health</i> , <b>2022</b> ,	14.5	4
185	Mortality in Persons With Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis.. <i>JAMA Pediatrics</i> , <b>2022</b> , e216401	8.3	4
184	The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990-2019: Findings from the Global Burden of Disease Study 2019.. <i>Lancet Regional Health - Europe, The</i> , <b>2022</b> , 16, 100341		10
183	Design and methodological characteristics of studies using observational routinely collected health data for investigating the link between cancer and neurodegenerative diseases: protocol for a meta-research study.. <i>BMJ Open</i> , <b>2022</b> , 12, e058738	3	
182	Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase. <i>European Journal of Clinical Pharmacology</i> , <b>2021</b> , 77, 1513-1521	2.8	2
181	Possible Ancestral Functions of the Genetic and RNA Operational Precodes and the Origin of the Genetic System. <i>Origins of Life and Evolution of Biospheres</i> , <b>2021</b> , 51, 167-183	1.5	0
180	Transcriptomic and Genetic Associations between Alzheimer's Disease, Parkinson's Disease, and Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
179	Lifestyle in Undergraduate Students and Demographically Matched Controls during the COVID-19 Pandemic in Spain. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	3
178	Use of multidimensional item response theory methods for dementia prevalence prediction: an example using the Health and Retirement Survey and the Aging, Demographics, and Memory Study. <i>BMC Medical Informatics and Decision Making</i> , <b>2021</b> , 21, 241	3.6	0
177	Is processing speed a valid neurocognitive endophenotype in bipolar disorder? Evidence from a longitudinal, family study. <i>Journal of Psychiatric Research</i> , <b>2021</b> , 141, 241-247	5.2	0
176	Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 1030-1049	35.1	15
175	Global, regional, and national burden of bone fractures in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. <i>The Lancet Healthy Longevity</i> , <b>2021</b> , 2, e580-e592	9.5	24
174	Lifestyle changes and mental health during the COVID-19 pandemic: A repeated, cross-sectional web survey. <i>Journal of Affective Disorders</i> , <b>2021</b> , 295, 173-182	6.6	3
173	Childhood trauma and substance use underlying psychosis: a systematic review. <i>Högre Utbildning</i> , <b>2020</b> , 11, 1748342	5	7
172	Interpreting molecular similarity between patients as a determinant of disease comorbidity relationships. <i>Nature Communications</i> , <b>2020</b> , 11, 2854	17.4	7
171	Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis. <i>Trials</i> , <b>2020</b> , 21, 34	2.8	6

170	Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. <i>Lancet, The, 2020, 396, 693-724</i>	40	32
169	Peripheral Oxidative Stress Markers in Patients with Bipolar Disorder during Euthymia and in Siblings. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 77-86</i>	2.2	5
168	Mapping child growth failure across low- and middle-income countries. <i>Nature, 2020, 577, 231-234</i>	50.4	62
167	Reproducible research practices, openness and transparency in health economic evaluations: study protocol for a cross-sectional comparative analysis. <i>BMJ Open, 2020, 10, e034463</i>	3	21
166	Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The, 2020, 396, 1204-1222</i>	40	1847
165	Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The, 2020, 396, 1223-1249</i>	40	1013
164	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The, 2020, 396, 1160-1203</i>	40	228
163	Five insights from the Global Burden of Disease Study 2019. <i>Lancet, The, 2020, 396, 1135-1159</i>	40	113
162	Motor and Cognitive Performance in Patients with Liver Cirrhosis with Minimal Hepatic Encephalopathy. <i>Journal of Clinical Medicine, 2020, 9,</i>	5.1	5
161	Grip Strength, Neurocognition, and Social Functioning in People With Type-2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia. <i>Frontiers in Psychology, 2020, 11, 525231</i>	3.4	2
160	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000-17. <i>The Lancet Global Health, 2020, 8, e1038-e1060</i>	13.6	12
159	Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study. <i>Injury Prevention, 2020, 26, i125-i153</i>	3.2	12
158	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The, 2020, 396, 1250-1284</i>	40	112
157	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000-17. <i>The Lancet Global Health, 2020, 8, e1162-e1185</i>	13.6	27
156	Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017. <i>Injury Prevention, 2020, 26, i96-i114</i>	3.2	39
155	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. <i>Injury Prevention, 2020, 26, i12-i26</i>	3.2	13
154	Morbidity and mortality from road injuries: results from the Global Burden of Disease Study 2017. <i>Injury Prevention, 2020, 26, i46-i56</i>	3.2	46
153	The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology, 2019, 4, 934-947</i>	18.8	167

152	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1749-1768	13.4	888
151	Association of Anorexia Nervosa With Risk of Cancer: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , <b>2019</b> , 2, e195313	10.4	6
150	Prevalence and comorbidity of autism spectrum disorder in Spain: study protocol for a systematic review and meta-analysis of observational studies. <i>Systematic Reviews</i> , <b>2019</b> , 8, 141	3	8
149	Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995-2050. <i>Lancet, The</i> , <b>2019</b> , 393, 2233-2260	40	158
148	Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer. <i>Molecular Autism</i> , <b>2019</b> , 10, 17	6.5	13
147	Reporting guidelines for health research: protocol for a cross-sectional analysis of the EQUATOR Network Library. <i>BMJ Open</i> , <b>2019</b> , 9, e022769	3	1
146	CIBERSAM: Ten years of collaborative translational research in mental disorders. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , <b>2019</b> , 12, 1-8	0.2	1
145	Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , <b>2019</b> , 18, 459-480	24.1	1093
144	Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , <b>2019</b> , 18, 376-393	24.1	201
143	Prevalence and comorbidity of attention deficit hyperactivity disorder in Spain: study protocol for extending a systematic review with updated meta-analysis of observational studies. <i>Systematic Reviews</i> , <b>2019</b> , 8, 49	3	3
142	Visual memory dysfunction as a neurocognitive endophenotype in bipolar disorder patients and their unaffected relatives. Evidence from a 5-year follow-up Valencia study. <i>Journal of Affective Disorders</i> , <b>2019</b> , 257, 31-37	6.6	5
141	The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 1211-1225	21.7	107
140	Neurocognitive endophenotypes in schizophrenia and bipolar disorder: A systematic review of longitudinal family studies. <i>Schizophrenia Research</i> , <b>2019</b> , 210, 21-29	3.6	14
139	The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 913-933	18.8	144
138	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. <i>Nature</i> , <b>2019</b> , 574, 353-358.	358.4	87
137	Cataracts and statins. A disproportionality analysis using data from VigiBase. <i>Regulatory Toxicology and Pharmacology</i> , <b>2019</b> , 109, 104509	3.4	2
136	Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , <b>2019</b> , 18, 357-375	24.1	252
135	Subjective neurocognition and quality of life in patients with bipolar disorder and siblings. <i>Journal of Affective Disorders</i> , <b>2019</b> , 245, 283-288	6.6	14

134	Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , <b>2019</b> , 18, 88-106	24.1	782
133	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , <b>2019</b> , 18, 56-87	24.1	480
132	The Burden of Cardiovascular Diseases Among US States, 1990-2016. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 375-389	16.2	184
131	Factors associated with poor functional outcome in bipolar disorder: sociodemographic, clinical, and neurocognitive variables. <i>Acta Psychiatrica Scandinavica</i> , <b>2018</b> , 138, 145-154	6.5	36
130	Duration of active psychosis and functional outcomes in first-episode non-affective psychosis. <i>European Psychiatry</i> , <b>2018</b> , 52, 29-37	6	13
129	The burden of disease in Spain: Results from the Global Burden of Disease 2016. <i>Medicina Clínica</i> , <b>2018</b> , 151, 171-190	1	55
128	Global Mortality From Firearms, 1990-2016. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 320, 792-814	27.4	114
127	Mapping of global scientific research in comorbidity and multimorbidity: A cross-sectional analysis. <i>PLoS ONE</i> , <b>2018</b> , 13, e0189091	3.7	17
126	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2018</b> , 392, 1736-1788	40	2850
125	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2018</b> , 392, 1923-1994	40	1964
124	Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2018</b> , 392, 1995-2051	40	189
123	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2018</b> , 392, 1789-1858	40	4524
122	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2018</b> , 392, 2091-2138	40	210
121	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2018</b> , 392, 1859-1922	40	1283
120	Epigenetic outlier profiles in depression: A genome-wide DNA methylation analysis of monozygotic twins. <i>PLoS ONE</i> , <b>2018</b> , 13, e0207754	3.7	10
119	Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2429-2437	59.2	495
118	Staging, Neurocognition and Social Functioning in Bipolar Disorder. <i>Frontiers in Psychiatry</i> , <b>2018</b> , 9, 709	5	12
117	Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , <b>2018</b> , 17, 939-953	24.1	785

116	Five Interpersonal Factors Are Predictive of the Response to Treatment of Major Depression With Antidepressants in Primary Care. <i>Frontiers in Psychiatry</i> , <b>2018</b> , 9, 416	5	8
115	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1553-1568	13.4	875
114	Do patients with bipolar disorder and subsyndromal symptoms benefit from functional remediation? A 12-month follow-up study. <i>European Neuropsychopharmacology</i> , <b>2017</b> , 27, 350-359	1.2	21
113	Clinical staging and serum cytokines in bipolar patients during euthymia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2017</b> , 77, 194-201	5.5	28
112	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. <i>JAMA Oncology</i> , <b>2017</b> , 3, 524-548	13.4	2394
111	Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1-25	15.1	1804
110	Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. <i>Psychopharmacology</i> , <b>2017</b> , 234, 2563-2570	4.7	21
109	Health Effects of Overweight and Obesity in 195 Countries over 25 Years. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 13-27	59.2	3027
108	Child and Adolescent Health From 1990 to 2015: Findings From the Global Burden of Diseases, Injuries, and Risk Factors 2015 Study. <i>JAMA Pediatrics</i> , <b>2017</b> , 171, 573-592	8.3	216
107	Cancer and central nervous system disorders: protocol for an umbrella review of systematic reviews and updated meta-analyses of observational studies. <i>Systematic Reviews</i> , <b>2017</b> , 6, 69	3	13
106	Manual motor speed dysfunction as a neurocognitive endophenotype in euthymic bipolar disorder patients and their healthy relatives. Evidence from a 5-year follow-up study. <i>Journal of Affective Disorders</i> , <b>2017</b> , 215, 156-162	6.6	12
105	The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. <i>PLoS ONE</i> , <b>2017</b> , 12, e0180355	3.7	132
104	Anorexia nervosa and cancer: a protocol for a systematic review and meta-analysis of observational studies. <i>Systematic Reviews</i> , <b>2017</b> , 6, 137	3	4
103	Risk of mortality among children, adolescents, and adults with autism spectrum disorder or attention deficit hyperactivity disorder and their first-degree relatives: a protocol for a systematic review and meta-analysis of observational studies. <i>Systematic Reviews</i> , <b>2017</b> , 6, 189	3	8
102	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1084-1150	40	421
101	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1151-1210	40	2542
100	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1211-1259	40	3432
99	Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Neurology, The</i> , <b>2017</b> , 16, 877-897	24.1	984

98	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1423-1459	4.0	224
97	Global, Regional, and National Levels of Maternal Mortality, 1990-2015: A Systematic Analysis for the Global Burden of Disease Study 2015. <i>Obstetrical and Gynecological Survey</i> , <b>2017</b> , 72, 11-13	2.4	18
96	A molecular hypothesis to explain direct and inverse co-morbidities between Alzheimer's Disease, Glioblastoma and Lung cancer. <i>Scientific Reports</i> , <b>2017</b> , 7, 4474	4.9	45
95	Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2017</b> , 267, 315-323	5.1	23
94	High cognitive reserve in bipolar disorders as a moderator of neurocognitive impairment. <i>Journal of Affective Disorders</i> , <b>2017</b> , 208, 621-627	6.6	40
93	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. <i>Lancet HIV, the</i> , <b>2016</b> , 3, e361-e387	7.8	382
92	The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review. <i>Systematic Reviews</i> , <b>2016</b> , 5, 6	3	18
91	Diagnosis and neurocognitive profiles in first-episode non-affective psychosis patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2016</b> , 266, 619-28	5.1	20
90	Functional remediation in bipolar disorder: 1-year follow-up of neurocognitive and functional outcome. <i>British Journal of Psychiatry</i> , <b>2016</b> , 208, 87-93	5.4	71
89	Mild cognitive decline. A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAH). <i>Maturitas</i> , <b>2016</b> , 83, 83-93	5	27
88	Rett Syndrome Mutant Neural Cells Lacks MeCP2 Immunoreactive Bands. <i>PLoS ONE</i> , <b>2016</b> , 11, e0153262	3.7	1
87	Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. <i>PLoS Medicine</i> , <b>2016</b> , 13, e1001971	11.6	61
86	Declaration of transparency: A step towards complete reporting of research articles. <i>Revista De Psiquiatria Y Salud Mental</i> , <b>2016</b> , 9, 63-4	2.7	9
85	Improving transparency of scientific reporting to increase value and reduce waste in mental health research. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , <b>2016</b> , 9, 1-3	0.2	
84	Effects of functional remediation on neurocognitively impaired bipolar patients: enhancement of verbal memory. <i>Psychological Medicine</i> , <b>2016</b> , 46, 291-301	6.9	30
83	Alzheimer's disease and cancer: the need of putting research into context with previous published systematic reviews. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2015</b> , 141, 569-70	4.9	2
82	Predictors of functional outcome after a manic episode. <i>Journal of Affective Disorders</i> , <b>2015</b> , 182, 121-5	6.6	11
81	The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: protocol for a systematic review and network meta-analysis of randomized controlled trials. <i>Systematic Reviews</i> , <b>2015</b> , 4, 19	3	28

80	Suicidal behaviour in first-episode non-affective psychosis: Specific risk periods and stage-related factors. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 2278-88	1.2	40
79	Functional remediation for patients with bipolar II disorder: improvement of functioning and subsyndromal symptoms. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 257-64	1.2	39
78	How does family intervention improve the outcome of people with schizophrenia?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , <b>2015</b> , 50, 379-87	4.5	15
77	Disability in bipolar I disorder: the 36-item World Health Organization Disability Assessment Schedule 2.0. <i>Journal of Affective Disorders</i> , <b>2015</b> , 174, 353-60	6.6	26
76	P.2.d.039 Functional remediation in bipolar II patients: improvement of functioning and subsyndromal symptoms. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, S436-S437	1.2	4
75	Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis. <i>Schizophrenia Research</i> , <b>2014</b> , 159, 90-4	3.6	29
74	Comparing neurocognitive impairment in schizophrenia and bipolar I disorder using the Screen for Cognitive Impairment in Psychiatry Scale. <i>International Journal of Clinical and Health Psychology</i> , <b>2014</b> , 14, 128-136	5.1	3
73	Alzheimer's disease and cancer: current epidemiological evidence for a mutual protection. <i>Neuroepidemiology</i> , <b>2014</b> , 42, 121-2	5.4	21
72	Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 17, 41-51	5.8	68
71	Molecular evidence for the inverse comorbidity between central nervous system disorders and cancers detected by transcriptomic meta-analyses. <i>PLoS Genetics</i> , <b>2014</b> , 10, e1004173	6	116
70	Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies. <i>Psychotherapy and Psychosomatics</i> , <b>2014</b> , 83, 89-105	9.4	113
69	Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. <i>Psychological Medicine</i> , <b>2014</b> , 44, 37-50	6.9	32
68	The impact of repeated manic episodes and executive dysfunction on work adjustment in bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2014</b> , 264, 247-54	5.1	28
67	The screen for cognitive impairment in psychiatry: diagnostic-specific standardization in psychiatric ill patients. <i>BMC Psychiatry</i> , <b>2013</b> , 13, 127	4.2	30
66	Psychometric behaviour of the strengths and difficulties questionnaire (SDQ) in the Spanish national health survey 2006. <i>BMC Psychiatry</i> , <b>2013</b> , 13, 95	4.2	44
65	Course of cognitive deficits in first episode of non-affective psychosis: a 3-year follow-up study. <i>Schizophrenia Research</i> , <b>2013</b> , 150, 121-8	3.6	31
64	Prediction of acute clinical response following a first episode of non affective psychosis: results of a cohort of 375 patients from the Spanish PAFIP study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2013</b> , 44, 162-7	5.5	28
63	Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. <i>Psychiatry Research</i> , <b>2013</b> , 206, 181-7	9.9	25



62	Predictors of neurocognitive impairment at 3 years after a first episode non-affective psychosis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2013</b> , 43, 23-8	5.5	16
61	The relevance of cognitive, clinical and premorbid variables in predicting functional outcome for individuals with first-episode psychosis: a 3 year longitudinal study. <i>Psychiatry Research</i> , <b>2013</b> , 209, 302-8 <sup>9</sup>	8.9	45
60	Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. <i>Nature Reviews Neuroscience</i> , <b>2013</b> , 14, 293-304	13.5	82
59	Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone. <i>Psychopharmacology</i> , <b>2013</b> , 227, 615-25	4.7	19
58	The clinical implications of cognitive impairment and allostatic load in bipolar disorder. <i>European Psychiatry</i> , <b>2013</b> , 28, 21-9	6	101
57	Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. <i>American Journal of Psychiatry</i> , <b>2013</b> , 170, 852-9	11.9	211
56	Human adult periodontal ligament-derived cells integrate and differentiate after implantation into the adult mammalian brain. <i>Cell Transplantation</i> , <b>2013</b> , 22, 2017-28	4	39
55	Neurocognitive impairment and psychosocial functioning in bipolar II disorder. <i>Acta Psychiatrica Scandinavica</i> , <b>2012</b> , 125, 309-17	6.5	62
54	One year longitudinal study of the straight gyrus morphometry in first-episode schizophrenia-spectrum patients. <i>Psychiatry Research - Neuroimaging</i> , <b>2012</b> , 202, 80-3	2.9	7
53	Neurocognitive impairment across the bipolar spectrum. <i>CNS Neuroscience and Therapeutics</i> , <b>2012</b> , 18, 194-200	6.8	54
52	Homocysteine and cognition in first-episode psychosis patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2012</b> , 262, 557-64	5.1	30
51	Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. <i>Journal of Psychiatric Research</i> , <b>2012</b> , 46, 1099-105	5.2	92
50	Developmental dynamics of PAFAH1B subunits during mouse brain development. <i>Journal of Comparative Neurology</i> , <b>2012</b> , 520, 3877-94	3.4	8
49	Utility of the World Health Organization Disability Assessment Schedule II in schizophrenia. <i>Schizophrenia Research</i> , <b>2012</b> , 138, 240-7	3.6	43
48	Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. <i>Schizophrenia Research</i> , <b>2012</b> , 141, 22-8	3.6	22
47	Neurocognitive training in patients with bipolar disorders: current status and perspectives. <i>Psychotherapy and Psychosomatics</i> , <b>2012</b> , 81, 250-2	9.4	18
46	Long-term outcome of cognitive impairment in bipolar disorder. <i>Journal of Clinical Psychiatry</i> , <b>2012</b> , 73, e899-905	4.6	114
45	Brief cognitive assessment instruments in schizophrenia and bipolar patients, and healthy control subjects: a comparison study between the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) and the Screen for Cognitive Impairment in Psychiatry (SCIP). <i>Schizophrenia Research</i> , <b>2011</b> , 130, 137-42	3.6	29

44	Therapeutic use of omega-3 fatty acids in bipolar disorder. <i>Expert Review of Neurotherapeutics</i> , <b>2011</b> , 11, 1029-47	4.3	74
43	Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. <i>Comprehensive Psychiatry</i> , <b>2011</b> , 52, 613-22	7.3	66
42	Straight gyrus morphology in first-episode schizophrenia-spectrum patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2011</b> , 35, 84-90	5.5	3
41	Sex-specific variation of MRI-based cortical morphometry in adult healthy volunteers: the effect on cognitive functioning. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2011</b> , 35, 616-23	5.5	17
40	No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. <i>Lancet Oncology</i> , <b>2011</b> , 12, 604-8	21.7	103
39	Global and regional cortical thinning in first-episode psychosis patients: relationships with clinical and cognitive features. <i>Psychological Medicine</i> , <b>2011</b> , 41, 1449-60	6.9	62
38	Poor long-term prognosis in mixed bipolar patients: 10-year outcomes in the Vitoria prospective naturalistic study in Spain. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 671-6	4.6	50
37	Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S). <i>Schizophrenia Research</i> , <b>2010</b> , 116, 243-51	3.6	40
36	Temporal pole morphology in first-episode schizophrenia patients: clinical correlations. <i>Psychiatry Research - Neuroimaging</i> , <b>2010</b> , 184, 189-91	2.9	8
35	Neurocognition in bipolar disorders--a closer look at comorbidities and medications. <i>European Journal of Pharmacology</i> , <b>2010</b> , 626, 87-96	5.3	79
34	Functional impairment in bipolar II disorder: is it as disabling as bipolar I?. <i>Journal of Affective Disorders</i> , <b>2010</b> , 127, 71-6	6.6	58
33	The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia. <i>BMC Psychiatry</i> , <b>2010</b> , 10, 47	4.2	10
32	Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients <b>2010</b> , 9,		78
31	Longitudinal course of cognition in schizophrenia. <i>British Journal of Psychiatry</i> , <b>2009</b> , 195, 84; author reply 85	5.4	2
30	Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. <i>Molecular Psychiatry</i> , <b>2009</b> , 14, 563-89	15.1	170
29	Comparative study of neurocognitive function in euthymic bipolar patients and stabilized schizophrenic patients. <i>Psychiatry Research</i> , <b>2009</b> , 169, 220-8	9.9	80
28	Functioning and disability in bipolar disorder: an extensive review. <i>Psychotherapy and Psychosomatics</i> , <b>2009</b> , 78, 285-97	9.4	273
27	Clinical usefulness of the screen for cognitive impairment in psychiatry (SCIP-S) scale in patients with type I bipolar disorder. <i>Health and Quality of Life Outcomes</i> , <b>2009</b> , 7, 28	3	28

26	The importance of negative comorbidity. <i>Journal of Clinical Psychiatry</i> , <b>2009</b> , 70, 1191-2; author reply 1192	4.6	5
25	Neurocognitive dysfunctions in euthymic bipolar patients with and without prior history of alcohol use. <i>Journal of Clinical Psychiatry</i> , <b>2009</b> , 70, 1120-7	4.6	50
24	Treatment nonadherence and neurocognitive impairment in bipolar disorder. <i>Journal of Clinical Psychiatry</i> , <b>2009</b> , 70, 1017-23	4.6	95
23	Motor speed predicts stability of cognitive deficits in both schizophrenic and bipolar I patients at one-year follow-up. <i>European Journal of Psychiatry</i> , <b>2009</b> , 23,	1	7
22	Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. <i>Journal of Affective Disorders</i> , <b>2008</b> , 109, 286-99	6.6	216
21	Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): psychometric properties of a brief scale for cognitive evaluation in schizophrenia. <i>Schizophrenia Research</i> , <b>2008</b> , 99, 139-48	3.6	60
20	Evidence for association between structural variants in lissencephaly-related genes and executive deficits in schizophrenia or bipolar patients from a Spanish isolate population. <i>Psychiatric Genetics</i> , <b>2008</b> , 18, 313-7	2.9	20
19	Neurocognitive endophenotypes (endophenocognitypes) from studies of relatives of bipolar disorder subjects: a systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2008</b> , 32, 1426-38	9	159
18	Functional impairment and previous suicide attempts in bipolar disorder. <i>Acta Neuropsychiatrica</i> , <b>2008</b> , 20, 300-6	3.9	12
17	Neurocognitive impairment in bipolar patients with and without history of psychosis. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 233-9	4.6	125
16	Functional outcome in bipolar disorder: the role of clinical and cognitive factors. <i>Bipolar Disorders</i> , <b>2007</b> , 9, 103-13	3.8	397
15	Cognitive impairment in schizoaffective disorder: a comparison with non-psychotic bipolar and healthy subjects. <i>Acta Psychiatrica Scandinavica</i> , <b>2007</b> , 116, 453-60	6.5	43
14	Bipolar I patients with and without a history of psychotic symptoms: do they differ in their cognitive functioning?. <i>Journal of Psychiatric Research</i> , <b>2007</b> , 41, 265-72	5.2	78
13	Neurodevelopmental mechanisms underlying psychosis. <i>International Clinical Psychopharmacology</i> , <b>2007</b> , 22, S1-S7	2.2	7
12	Postnatal alterations of the inhibitory synaptic responses recorded from cortical pyramidal neurons in the Lis1/sLis1 mutant mouse. <i>Molecular and Cellular Neurosciences</i> , <b>2007</b> , 35, 220-9	4.8	14
11	Specificity of cognitive deficits in bipolar disorder versus schizophrenia. A systematic review. <i>Psychotherapy and Psychosomatics</i> , <b>2006</b> , 75, 72-84	9.4	160
10	Variations in genes regulating neuronal migration predict reduced prefrontal cognition in schizophrenia and bipolar subjects from mediterranean Spain: a preliminary study. <i>Neuroscience</i> , <b>2006</b> , 139, 1289-300	3.9	36
9	The high-activity Val allele of the catechol-O-methyltransferase gene predicts greater cognitive deterioration in patients with psychosis. <i>Psychiatric Genetics</i> , <b>2006</b> , 16, 213-6	2.9	20

8	Persistent cognitive dysfunctions in bipolar I disorder and schizophrenic patients: a 3-year follow-up study. <i>Psychotherapy and Psychosomatics</i> , <b>2005</b> , 74, 113-9	9.4	125
7	Recall and recognition confabulation in psychotic and bipolar disorders: evidence for two different types without unitary mechanisms. <i>Comprehensive Psychiatry</i> , <b>2004</b> , 45, 281-8	7.3	32
6	Specific executive/attentional deficits in patients with schizophrenia or bipolar disorder who have a positive family history of psychosis. <i>Journal of Psychiatric Research</i> , <b>2003</b> , 37, 479-86	5.2	41
5	Abnormal motor asymmetry only during bimanual movement in schizophrenic patients compared with healthy subjects. <i>Schizophrenia Research</i> , <b>2003</b> , 61, 245-53	3.6	9
4	Similar effect of family history of psychosis on Sylvian fissure size and auditory P200 amplitude in schizophrenic and bipolar subjects. <i>Psychiatry Research - Neuroimaging</i> , <b>2001</b> , 108, 29-38	2.9	12
3	Correlates of symptom dimensions in schizophrenia obtained with the Spanish version of the Manchester scale. <i>Psychopathology</i> , <b>2000</b> , 33, 259-64	3.4	13
2	Early age of onset, brain morphological changes and non-consistent motor asymmetry in schizophrenic patients. <i>Schizophrenia Research</i> , <b>1999</b> , 37, 225-31	3.6	11
1	Unveiling the molecular basis of disease co-occurrence: towards personalized comorbidity profiles		1